Court Ruling Compels Plan B One-Step And Generics Over The Counter
This article was originally published in The Tan Sheet
Executive Summary
Under a federal judge’s order, FDA must reverse its denial of the Center for Reproductive Rights’ 12-year-old citizen petition and allow universal OTC access to levonorgestrel-based emergency contraceptives within 30 days.
You may also be interested in...
Judge Likely To Order Lower Age Restriction For Emergency Contraceptives
A federal judge seems inclined to order FDA to make emergency contraceptives available OTC to women younger than 17, but he did not say whether the use would be limited to Teva’s Plan B One-Step, or would include all nonprescription levonorgestrel products.
FDA Contests Court Intervention On Plan B As Teva Argues For Exclusivity
In CRR’s lawsuit, FDA and Teva argue that the firm’s potential for OTC market exclusivity for Plan B One-Step should be protected. But while Teva is open to judicial intervention on whether to allow universal OTC sales, FDA says precedent supports judicial deference to agency scientific decisions.
Teva Plan B OTC Application Fails Political Test After Clearing FDA Hurdle
HHS Secretary Sebelius says Teva must show more evidence of how young adolescent females would use Plan B One-Step as an OTC. But obtaining such clinical data for the emergency contraceptive – in excess of what FDA already needed to approve it – appears nearly impossible, experts say.